Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative DiseaseBusiness Wire • 06/22/22
Press release Biocartis Group NV: Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso®GlobeNewsWire • 06/22/22
AstraZeneca, Ionis plan to seek FDA approval for rare-disease therapy this yearMarket Watch • 06/21/22
AstraZeneca hails phase III success of drug for rare disease amyloid polyneuropathyProactive Investors • 06/21/22
TROPION-Breast02 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Previously Untreated Metastatic Triple Negative Breast CancerBusiness Wire • 06/13/22
EpimAb Biotherapeutics Announces U.S. FDA Clearance of IND Application for Phase Ib/II Trial of EMB-01 in Combination with Tagrisso® for Non-Small Cell Lung CancerBusiness Wire • 06/08/22
ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative DiseaseBusiness Wire • 06/05/22
GRAIL Announces Strategic Collaboration With AstraZeneca to Develop Companion Diagnostic Tests to Enable the Treatment of Early-Stage CancerBusiness Wire • 06/02/22
Cancer treatments may benefit from lessons of pandemic set-backs -AstraZeneca executiveReuters • 05/26/22